Adagio Medical Holdings Inc (ADGM)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$0.06-29.23%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · ADGM
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
As of March 31, 2026.
Stated in 1 of 2 supplied quarters. Management reported: “As of March 31, 2026.” “The PMA submission is supported by the FULCRUM-VT pivotal IDE trial, a single-arm study that enrolled 209 patients across 20 leading electrophysiology centers.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“As of March 31, 2026.”
Reported cash and cash equivalents of $12.9 million as of March 31, 2026.
Stated in 1 of 2 supplied quarters. Management reported: “Reported cash and cash equivalents of $12.9 million as of March 31, 2026.” “Net loss for the three months ended March 31, 2026 was $7.0 million, compared to a net loss of $7.7 million for the three months ended March 31, 2025.” Net income was $-6.995 million in 2026-Q1.
“Reported cash and cash equivalents of $12.9 million as of March 31, 2026.”
As of March 31, 2026.
Stated in 2 of 2 supplied quarters. Management reported: “As of March 31, 2026.” “Reported cash and cash equivalents of $12.9 million as of March 31, 2026.”
“As of March 31, 2026.”
“Reported cash and cash equivalents of $12.9 million as of March 31, 2026.”
Continue clinical development and regulatory submission of ULTA technology, including PMA application for vCLAS system supported by FULCRUM-VT pivotal trial data.
Continue to generate and present clinical data demonstrating safety and effectiveness of ULTA technology in VT ablation, including pivotal trial results.
Over the trailing year it converted 1.28x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
18 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.